Aurora Cannabis Stock (TSX:ACB) (OTC:ACBFF) - Investor Dashboard

Aurora Cannabis
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees: >1400 as of 9/2018
Established: 2013
CEO: Terry Booth


Fiscal Year-End: June 30
Licensed Facilities: 11
Dried Flower: Production and Sale
Extracts: Production and Sale
Number of Patients: 45,776
Headquarters: Vancouver, BC

Financials (06/30/18)

Cash on hand: $90.2mm
Fixed Investment: $246.4mm
Shareholders’ Equity: $1.56 billion
Revenues – Last Quarter: $19.2mm
Adj. Gross Margin: 68.2%
EPS : n/a

Capital Structure (09/25/18)

Last Equity Fin: $230mm Convertible Notes at $13.05
Basic Shares: 963.7mm
Warrants: 23.0mm
Options: 42.8mm
Diluted Shares: 1047.4mm

Company Brief

Aurora is one of the world’s largest and fastest growing cannabis companies. Following the acquisition of MedReleaf, the company has more than 1,200 employees, nine facilities in Canada, two facilities in Europe, and a funded annual production capacity of more than 500,000 kilograms. The company advanced its vertical integration strategy with the acquisition of cannabis biotechnology company Anandia Laboratories. Aurora has created a growing constellation of subsidiaries and strategic partnerships that provide differentiation in terms of geographic reach, production, technology, product offering, and execution.

With a growing number of countries adopting medical cannabis legislation, the Company has embarked on an aggressive international expansion strategy that currently sees Aurora with operations and/or sales and participation across five continents.


Canadian Operations

  • Multiple state-of-the-art facilities in operation or under construction:
    • Alberta: Aurora Sky, Aurora MTN, and Aurora Sun
    • Saskatchewan: CanniMed (acquired in 2018)
    • Quebec: Aurora VIA and H2 Biopharma
    • Ontario: MedReleaf (pending $2.51 billion acquisition)
  • Acquisition of MedReleaf brings the company’s annual production capacity up to 570,000 kilograms through nine facilities in Canada in and two in Europe
  • All products certified by testing through Anandia Laboratories
  • Acquisition of Anandia Laboratories gives the company access to new revenue streams including tissue culture archiving, genetic testing, and predictive chemotype profiling
  • Only LP with tissue micro-propagation lab
  • Unique Temple strain with CBD tested at 24%
  • Ownership of CanvasRx, the largest operator of cannabis clinics in Canada with 28 facilities open
  • Same-day delivery in Alberta and innovative mobile ordering app
  • Supply agreements with Alberta Gaming, Liquor and Cannabis Commission and the Ontario Cannabis Store
  • Agreements with PharmaChoice, Pharmasave, and Shoppers Drug Mart to distribute and sell medical cannabis
  • Strong product portfolio with Aurora, CanniMed, and MedReleaf brands and wellness brands including San Rafael ’71, Woodstock, and AltaVie

Global Operations

  • Active in nine international markets: Australia, Brazil, Cayman Islands, Colombia, Denmark, Germany, Italy, Malta, and South Africa
  • 22.9% ownership of Australia’s Cann Group (ASX: CAN)
  • Ownership of German distribution company Pedanios
  • 51% ownership of Aurora Nordic in Denmark
  • Medical cannabis supply agreement with the Italian government
  • Approved for the first cannabis cultivation facility in Malta
  • Acquired European hemp company Agropro and sister company Borela
  • 22.9% investment in Austrailian company Cann Group
  • Supply agreement in South Africa
  • Large investment portfolio including TGOD, Radient Technologies, Hempco, Alcanna (formerly Liquor Stores N.A.), and more

Cam Battley, EVP of Aurora Cannabis (TSX: ACB) (OTC: ACBFF), presented at the New West Summit in Oakland on October 13, 2017

Cam Battley, CCO of Aurora Cannabis, speaks with Cannabis Editor, Mark Rendell, about his company’s ambition and partnership deals and explains that the cannabis industry is “a bit like a land grab”.

Institutional Analyst Coverage


GMP Securities

PI Financial

Mackie Research

Curated Stories & News

Visit Aurora Cannabis

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Aurora Cannabis is a client of NCV Media, LLC. Read our full disclaimer.